Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New risk model could help predict superbug infections in ICUs

NCT ID NCT07603128

Knowledge-focused Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a risk prediction model for MDRGNB, a type of drug-resistant infection, in 1,000 ICU patients across multiple hospitals. Researchers will check how well the model predicts who gets infected, using data collected within 48 hours of ICU admission. The goal is to improve early detection and guide antibiotic use, but this is an observational study, not a treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a reliable tool for predicting MDRGNB infections in ICU patients, helping doctors start the right antibiotics sooner.
What could go wrong
This is an observational study, not a treatment trial. The model may not perform as well in real-world settings, and results may not apply to all hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult ICU patients

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years; * ICU stay ≥48 hours; * At least one clinical microbiological specimen collected and submitted for testing within 48 hours of ICU admission, with the first submission time designated as the index time; * Core predictive variables of the model extractable from electronic medical records or laboratory information systems. Exclusion Criteria: * For patients with multiple ICU admissions, only the first ICU stay was retained; * Missing or indeterminate primary outcome; * Missing key predictive variables that could not be handled according to prespecified rules.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Infections infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ankang People's Hospital

    NOT_YET_RECRUITING

    Ankang, China

  • First Affiliated Hospital of Gannan Medical University

    NOT_YET_RECRUITING

    Ganzhou, China

  • Guangxi Provincial Tumor Hospital

    RECRUITING

    Nanning, China

  • Huaian First People's Hospital

    NOT_YET_RECRUITING

    Huaian, China

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, Jiangsu, 210008, China

  • Shaanxi Provincial People's Hospital

    NOT_YET_RECRUITING

    Xi'an, China

  • Shanghai Ruijin Hospital

    RECRUITING

    Shanghai, China

  • Sinopharm Tongmei General Hospital

    NOT_YET_RECRUITING

    Datong, China

  • Zhanjiang Central People's Hospital

    NOT_YET_RECRUITING

    Zhanjiang, China

  • Zhejiang Hospital

    RECRUITING

    Hangzhou, China

  • Zhejiang Provincial People's Hospital

    NOT_YET_RECRUITING

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.